Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US10000511B2
公开(公告)日:2018-06-19
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
Chemical entities that kill senescent cells for use in treating age-related disease
申请人:Unity Biotechnology, Inc.
公开号:US10195213B2
公开(公告)日:2019-02-05
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS
申请人:Walensky Loren D.
公开号:US20130035304A1
公开(公告)日:2013-02-07
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
COMPOUNDS AND THERAPEUTIC USES
申请人:Unity Biotechnology, Inc.
公开号:US20170281649A1
公开(公告)日:2017-10-05
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
An efficient and green method for the synthesis of Betti base employing nano-SiO2–H3BO3 as a novel recyclable heterogeneous catalyst
research, nano-SiO2–H3BO3 is introduced as a novel environmentally benign and recyclable heterogeneous catalyst for the synthesis of aminonaphthols under solvent-free conditions without an additional co-catalyst or additive in air. This synthesismethod offers several advantages, such as a green and eco-friendly protocol, operational simplicity, mild reaction conditions, short reaction times, higher yields
摘要 在这项研究中,引入了纳米SiO 2 -H 3 BO 3作为一种新型的环境友好型可循环使用的非均相催化剂,用于在无溶剂条件下合成氨基萘,而无需额外的助催化剂或空气中的添加剂。这种合成方法具有许多优点,例如绿色环保的方法,操作简单,反应条件温和,反应时间短,产率高,后处理程序容易。这些非常干净的反应的后处理仅涉及从乙醇中重结晶产物并通过过滤回收催化剂。催化剂可以重复使用几次而不会失去活性。 图形概要